West Nile Virus in Europe and Safety of Blood Transfusion

Pisani, Giulio; Cristiano, Karen; Pupella, Simonetta; Liumbruno, Giancarlo Maria

doi:10.1159/000446219

Cited by 100 publications

(61 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This also fits with the lack of cases in donors; no donation has been confirmed to be WNV‐positive. Germany, another non‐affected area, also experienced zero confirmed WNV positives in their first season of testing, with 0·9% of blood donations tested where donors had mainly travelled to Italy, Croatia, Greece and the United States (Dreier et al, ), whereas Italy, with affected areas, identified 57 of 1144675 donations as positive (0·005%, range 0·00–0·01%) between 2011 and 2015 (Pisani et al, ). NHSBT, which tests donations for WNV in a non‐affected country, have considered that testing in pools of six continues to ensure that the required level of sensitivity is maintained in a cost‐effective way rather than move to singleton testing.…”

Section: Discussionmentioning

confidence: 99%

Who do we gain? Enhancement of blood supplies by additional testing for donors who travel

Reynolds

Cieply

Sell

et al. 2019

Transfusion Medicine

View full text Add to dashboard Cite

SUMMARY Aims/Objectives To describe the impact of additional testing on the England blood supply. Background The blood service for England, NHS Blood and Transplant, applies a system of deferral and testing to donors with potential exposure to Chagas disease, malaria and West Nile virus; however, testing costs must be justified. Here, we describe the donations and donors gained by testing. Methods Donation testing results and demographic data on donors in England where additional testing was applied were analysed in 2012–2016. The total number and proportion of donations tested, reactive and confirmed positive were calculated. Proportions of donors requiring additional tests were calculated by ethnic group for first‐time and repeat donors. Results Additional testing for travel was applied to 3·5% of NHSBT blood donations between 2012 and 2016. Over 98% of these tests were non‐reactive. Only malaria tests were confirmed positive, in 1·7% of donations tested. In first‐time donors, 45 and 40% of Asian and Black donors required an additional test, respectively, mainly for malaria. Testing for West Nile virus increased from 1·5% in 2012 to 2·2% of donations in 2016. Conclusion The majority of additional tests were screened negative, allowing approximately 64 000 donations to be released for issue annually. Donors most affected by malaria testing were more likely to have rare blood groups and be targeted for recruitment, whereas those given West Nile virus testing were mainly regular donors required for continuity of supply. These data show differences in the characteristics of donors by test and can be used to inform decisions about additional testing and deferrals.

show abstract

Section: Discussionmentioning

confidence: 99%

Who do we gain? Enhancement of blood supplies by additional testing for donors who travel

Reynolds

Cieply

Sell

et al. 2019

Transfusion Medicine

View full text Add to dashboard Cite

show abstract

“…This may also apply for countries endemic for ZIKV. After the WNV outbreak, some European countries have introduced a selectively WNV NAT based on travel history . The risk of a ZIKV outbreak in Europe is feasible since one of its vectors, Ae.…”

Section: Discussionmentioning

confidence: 99%

“…After the WNV outbreak, some European countries have introduced a selectively WNV NAT based on travel history. 31 The risk of a ZIKV outbreak in Europe is feasible since one of its vectors, Ae. albopictus, is present in South Europe and ZIKV imported cases into Europe have been reported.…”

Section: Discussionmentioning

confidence: 99%

Zika virus RNA polymerase chain reaction on the utility channel of a commercial nucleic acid testing system

2018

View full text Add to dashboard Cite

show abstract

“…Screening for WNV by nucleic acid test was implemented in the United States in 2003. Since 2004, blood centres in the EU have been obliged to either defer donors for 28 days after travelling to or living in endemic areas or implement blood screening procedures .…”

Section: Some Current Eids Relevant For Blood Safetymentioning

confidence: 99%

Emerging infectious diseases and blood donation

Kjerulff

Erikstrup

2018

ISBT Science Series

View full text Add to dashboard Cite

Emerging infectious diseases (EIDs) require vigilance from blood banks everywhere. As EIDs spread to new areas and populations, blood banks are forced to re‐evaluate safety measures continually. Screening, pathogen inactivation and deferral policies must be balanced against supply, safety and cost‐effectiveness. One size does not fit all, and blood banks must adjust to local needs and conditions when considering initiation or halting of screening, pathogen inactivation or deferral procedures to balance between demand/supply, safety and economy.

show abstract

West Nile Virus in Europe and Safety of Blood Transfusion

Cited by 100 publications

References 52 publications

Who do we gain? Enhancement of blood supplies by additional testing for donors who travel

Who do we gain? Enhancement of blood supplies by additional testing for donors who travel

Zika virus RNA polymerase chain reaction on the utility channel of a commercial nucleic acid testing system

Emerging infectious diseases and blood donation

Contact Info

Product

Resources

About